Hong Kong Pharma Digital Technology Holdings LTD F-1 registration statements

Cellyan Biotechnology Co., Ltd. filed an F-1 registration statement for the resale of up to 12.5 million Class A Ordinary Shares by selling shareholders, while facing a Nasdaq minimum bid price deficiency and significant corporate governance changes.

Hong Kong Pharma Digital Technology Holdings Limited, a Cayman Islands holding company, has filed for an initial public offering of its ordinary shares on the Nasdaq Capital Market, aiming to raise capital for business expansion.

Hong Kong Pharma Digital Technology Holdings Limited has issued warrants to Bancroft Capital, LLC, as part of an underwriting agreement, allowing the purchase of ordinary shares at a set price.

Hong Kong Pharma Digital Technology Holdings Limited, a Cayman Islands holding company, has filed for an initial public offering of 1,500,000 ordinary shares on the Nasdaq Capital Market.

Hong Kong Pharma Digital Technology Holdings Limited files for an initial public offering of 1,500,000 ordinary shares, aiming for a Nasdaq listing to fuel its OTC pharmaceutical supply chain and distribution business.